Biotechnológiai fejlesztések a monoklonálisantitest- terápiában

a RANK-ligand-gátló antitest

Translated title of the contribution: Biotechnological advances in monoclonal antibody therapy: The RANK ligand inhibitor antibody

E. Kiss, Zénó Kuluncsics, Zoltán Kiss, G. Poór

Research output: Contribution to journalArticle

Abstract

Biological drugs have been used since the middle of the last century in medicine. Nowadays we are witnesses of the intensive development and wider administration of these drugs in clinical practice. Around 250 biological drugs are available and more than 350 million patients have been treated since their marketed authorization. Among the biologics there are protein based macromolecules, which mass production can be performed with the help of biotechnology. This term referring to the use of living organisms for production of molecules, was introduced by the Hungarian engineer, Károly Ereky. The present review focuses on the research, production and development of monoclonal antibodies manufactured by biotechnology. Some steps of this development have changed our immunological knowledge and the outcome of several diseases. The development of antibodies was highly recognized by two Nobel prizes. Authors detail the structure and functions of immunoglobulins, and their development, including fully human monoclonal antibodies. The RANKL inhibitor denosumab, a fully human IgG2 monoclonal antibody belongs to this latter group and it is available for treatment of osteoporosis. Authors also summarize the basic process of bone metabolism and the benefits of RANK ligand inhibition.

Original languageHungarian
Pages (from-to)2137-2144
Number of pages8
JournalOrvosi Hetilap
Volume151
Issue number52
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

RANK Ligand
Monoclonal Antibodies
Biotechnology
Antibodies
Pharmaceutical Preparations
Nobel Prize
Biological Products
Osteoporosis
Immunoglobulins
Therapeutics
Immunoglobulin G
Medicine
Bone and Bones
Research
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biotechnológiai fejlesztések a monoklonálisantitest- terápiában : a RANK-ligand-gátló antitest. / Kiss, E.; Kuluncsics, Zénó; Kiss, Zoltán; Poór, G.

In: Orvosi Hetilap, Vol. 151, No. 52, 01.12.2010, p. 2137-2144.

Research output: Contribution to journalArticle

@article{17126dc52dd24d85b94fd91e48bf1830,
title = "Biotechnol{\'o}giai fejleszt{\'e}sek a monoklon{\'a}lisantitest- ter{\'a}pi{\'a}ban: a RANK-ligand-g{\'a}tl{\'o} antitest",
abstract = "Biological drugs have been used since the middle of the last century in medicine. Nowadays we are witnesses of the intensive development and wider administration of these drugs in clinical practice. Around 250 biological drugs are available and more than 350 million patients have been treated since their marketed authorization. Among the biologics there are protein based macromolecules, which mass production can be performed with the help of biotechnology. This term referring to the use of living organisms for production of molecules, was introduced by the Hungarian engineer, K{\'a}roly Ereky. The present review focuses on the research, production and development of monoclonal antibodies manufactured by biotechnology. Some steps of this development have changed our immunological knowledge and the outcome of several diseases. The development of antibodies was highly recognized by two Nobel prizes. Authors detail the structure and functions of immunoglobulins, and their development, including fully human monoclonal antibodies. The RANKL inhibitor denosumab, a fully human IgG2 monoclonal antibody belongs to this latter group and it is available for treatment of osteoporosis. Authors also summarize the basic process of bone metabolism and the benefits of RANK ligand inhibition.",
keywords = "antibody, biotechnology, monoclonal, RANK ligand",
author = "E. Kiss and Z{\'e}n{\'o} Kuluncsics and Zolt{\'a}n Kiss and G. Po{\'o}r",
year = "2010",
month = "12",
day = "1",
doi = "10.1556/OH.2010.29010",
language = "Hungarian",
volume = "151",
pages = "2137--2144",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "52",

}

TY - JOUR

T1 - Biotechnológiai fejlesztések a monoklonálisantitest- terápiában

T2 - a RANK-ligand-gátló antitest

AU - Kiss, E.

AU - Kuluncsics, Zénó

AU - Kiss, Zoltán

AU - Poór, G.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Biological drugs have been used since the middle of the last century in medicine. Nowadays we are witnesses of the intensive development and wider administration of these drugs in clinical practice. Around 250 biological drugs are available and more than 350 million patients have been treated since their marketed authorization. Among the biologics there are protein based macromolecules, which mass production can be performed with the help of biotechnology. This term referring to the use of living organisms for production of molecules, was introduced by the Hungarian engineer, Károly Ereky. The present review focuses on the research, production and development of monoclonal antibodies manufactured by biotechnology. Some steps of this development have changed our immunological knowledge and the outcome of several diseases. The development of antibodies was highly recognized by two Nobel prizes. Authors detail the structure and functions of immunoglobulins, and their development, including fully human monoclonal antibodies. The RANKL inhibitor denosumab, a fully human IgG2 monoclonal antibody belongs to this latter group and it is available for treatment of osteoporosis. Authors also summarize the basic process of bone metabolism and the benefits of RANK ligand inhibition.

AB - Biological drugs have been used since the middle of the last century in medicine. Nowadays we are witnesses of the intensive development and wider administration of these drugs in clinical practice. Around 250 biological drugs are available and more than 350 million patients have been treated since their marketed authorization. Among the biologics there are protein based macromolecules, which mass production can be performed with the help of biotechnology. This term referring to the use of living organisms for production of molecules, was introduced by the Hungarian engineer, Károly Ereky. The present review focuses on the research, production and development of monoclonal antibodies manufactured by biotechnology. Some steps of this development have changed our immunological knowledge and the outcome of several diseases. The development of antibodies was highly recognized by two Nobel prizes. Authors detail the structure and functions of immunoglobulins, and their development, including fully human monoclonal antibodies. The RANKL inhibitor denosumab, a fully human IgG2 monoclonal antibody belongs to this latter group and it is available for treatment of osteoporosis. Authors also summarize the basic process of bone metabolism and the benefits of RANK ligand inhibition.

KW - antibody

KW - biotechnology

KW - monoclonal

KW - RANK ligand

UR - http://www.scopus.com/inward/record.url?scp=78650379373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650379373&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.29010

DO - 10.1556/OH.2010.29010

M3 - Article

VL - 151

SP - 2137

EP - 2144

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 52

ER -